Two patients with the same endometriosis diagnosis often have measurably different disease.
We make that difference visible.
The heterogeneity problem
Since 1985, endometriosis has been staged by anatomy: the location and depth of lesions, whether an endometrioma sits on the ovary, whether deep infiltrating endometriosis reaches behind the uterus. That system is useful for surgical planning, but it does not capture the biological variation between patients that drives treatment decisions.
Two patients with identical Stage II disease can have categorically different biology. One may show high estrogen receptor expression. Another, a chronic inflammatory infiltrate. A third, fibrosis embedding the lesion in scar. A fourth, neuroinflammatory invasion and the central sensitization that keeps pain going long after the lesions are treated.
Standard staging does not see this. We do. Endometriosis is typically characterized by anatomy. Perita characterizes endometriosis by biology.
Two patients. Same diagnosis. Different biology.
A Stage II diagnosis reads the same on paper. The biology underneath can diverge completely.
Estrogen-driven
01 · MOLECULAR CHARACTERIZATION
ESTROGEN-DRIVEN
High estrogen receptor expression, low immune infiltration, minimal fibrosis.
02 · WHAT THIS GIVES HER PHYSICIAN
A clearer biological starting point to weigh alongside her history, imaging, and prior treatment response. The decision that follows is her physician's.
Inflammatory
01 · MOLECULAR CHARACTERIZATION
INFLAMMATORY
Heavy immune infiltrate, an exhaustion signature, elevated cytokines, with estrogen signaling in the typical range.
02 · WHAT THIS GIVES HER PHYSICIAN
A different biological picture, and a different starting point for the same conversation. What comes next is a clinical decision, made by her physician with her.
Same staging. Same anatomy. Two distinct biological pictures. Perita characterizes the difference. The treating physician decides what it means.
How We Characterize
Our process begins with individualized molecular testing, run on a blood sample and, where available, lesion tissue obtained during a laparoscopy or excision surgery. From these results, Perita builds a multi-layered portrait of a patient's disease at cellular, spatial, and signaling resolution, using cutting-edge analytical tools. What is present is named. What is missing is identified. Where it sits in the tissue is mapped.
A lesion is not a lump. It is a community.
Endometriotic tissue functions as an ecosystem of cell types, signaling, and structure. We characterize all of it.
VASCULATURE
Recruited blood supply that feeds the lesion and complicates removal.
EPITHELIAL CELLS
The lesion proper. Origin uncertain, behavior far from simple.
IMMUNE POPULATIONS
T cells, macrophages, NK cells. Often present, often not doing their jobs.
NERVE INFILTRATION
Fibers that grow into the lesion, driving pain disproportionate to size.
STROMAL SCAFFOLD
Fibroblasts, matrix, mechanical signaling. The architecture that holds the rest.
A treatment chosen without seeing this picture is a treatment chosen in the dark.
From Characterization to Clinical Decision
Perita delivers its analysis to the patient's treating physician as a written Deep Endometriosis Characterization™ report. The molecular portrait can inform care, but it is not a treatment plan. The physician weighs the report alongside clinical history, examination findings, imaging, prior treatment response, patient preference, and their own judgment.
The report maps the therapeutic categories to which the patient's biology may be relevant. It is a reference resource for treating physicians, not a prescription, a recommendation, or a substitute for clinical judgment.
What Ongoing Means
Deep Endometriosis Characterization™ is just the beginning of the relationship with Perita. We analyze data at defined intervals, run repeat molecular profiling, and document how the patient's biology changes over time. The Perita Scientific Advisory Board reviews the longitudinal record and provides an updated report to the patient's treating physician. The patient and their physician decide what comes next in their treatment journey.
The Dataset we are Building
Every characterization contributes to a longitudinal, multi-omics dataset that did not exist before Perita. With patient consent, the de-identified molecular profile becomes part of a research-grade dataset that captures how this disease behaves across patients and over time.
Our Framework
Perita uses cutting-edge analytical tools to deliver Deep Endometriosis Characterization™ for each patient.
Endometriosis has waited a long time for this. We are doing it now.